Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
BridgeBio Pharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
BBIO
Nasdaq
2834
http://bridgebio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for BridgeBio Pharma Inc
BridgeBio Pharma Posts Early Data From Neurological Movement Disorder Candidate
- May 26th, 2022 5:38 pm
BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias
- May 26th, 2022 5:00 pm
BridgeBio Partnered Protein Replacement Therapy Shows Promising Action In Painful Skin Blistering Disorder
- May 20th, 2022 7:04 pm
BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
- May 20th, 2022 11:30 am
Biotech Stock Roundup: BBIO Up on BMY Deal, GILD & CMRX Offer Updates
- May 18th, 2022 3:41 pm
BridgeBio Pharma to Participate in May Investor Events
- May 17th, 2022 11:30 am
BridgeBio (BBIO) Up on Deal With BMY for SHP2 Inhibitor
- May 13th, 2022 6:29 pm
10 Amazing Stocks Under $10 (Part II)
- May 13th, 2022 2:35 pm
BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two Years
- May 13th, 2022 11:30 am
BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology
- May 12th, 2022 1:48 pm
BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology
- May 12th, 2022 11:30 am
What Does The Future Hold For BridgeBio Pharma, Inc. (NASDAQ:BBIO)? These Analysts Have Been Cutting Their Estimates
- May 12th, 2022 10:13 am
BridgeBio Pharma to Participate in the Bank of America Securities Healthcare Conference
- May 10th, 2022 8:30 pm
BridgeBio Shares Plunge After it Details Out-Licensing Plans For 'Restructuring Initiative'
- May 5th, 2022 7:37 pm
BridgeBio Pharma (BBIO) Reports Q1 Loss, Misses Revenue Estimates
- May 5th, 2022 12:45 pm
BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update
- May 5th, 2022 11:30 am
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates
- May 4th, 2022 10:05 pm
BridgeBio Pharma (BBIO) Stock Sinks As Market Gains: What You Should Know
- Apr 28th, 2022 10:15 pm
BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- Apr 3rd, 2022 12:36 pm
BridgeBio Pharma to Present Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American College of Cardiology (ACC) Annual Scientific Session & Expo
- Mar 28th, 2022 11:30 am
Scroll